CLINICAL_TRIALS
trial_result
· 2024-09-05
Clinical Trial Update: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment [Phase 3]
Summary
A Phase 3 global trial evaluating obeticholic acid for nonalcoholic steatohepatitis with fibrosis was terminated, and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Intercept Pharmaceuticals | Conditions: Non Alcoholic Steatohepatitis (NASH) | Phase 3 | Status: TERMINATED | Results posted: 2024-09-05